United States Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the United States Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

United States Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The su rprise victory of Donald Trump in the US presidential election provides something of a mixed bag for multinational drugmakers ' revenue-earning opportunities in the country . Indeed, while potentially lower medicine expenditure poses downside risk to our projections for pharmaceutical spending, in contrast, lower tax rates and a subsequent boost in corporate activity pose upside risk . Nevertheless, d rug pricing remains th e key issue worrying drugmakers and this concern has been present well before both Trump and Hillary Clinton started their campaigns. As such, w e are maintaining our curre nt forecasts for pharmaceutical and healthcare expenditure in the US.

Headline Expenditure Projections

  • Pharmaceuticals : USD371bn in 2016 to USD390bn in 2017; +5.2% growth. Market forecast unchanged since Q416 update.

  • Healthcare : USD3,281bn in 2016 to USD3,440bn in 2017; +4.8% growth. Market forecast unchanged since Q416 update.

Headline Pharmaceuticals & Healthcare Forecasts (United States 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 316.339 343.605 370.929 390.275 402.900 415.973 429.469
Pharmaceutical sales, % of GDP 1.82 1.92 1.99 2.02 2.01 2.00 1.99
Pharmaceutical sales, % of health expenditure 10.6 10.9 11.3 11.3 11.3 11.1 11.0
Health spending, USDbn 2,985.748 3,139.179 3,280.775 3,439.511 3,577.456 3,735.317 3,904.267

Risk/Reward Index

The US pharmaceutical market ranks first both regionally and globally within BMI's Pharmaceutical Risk/Reward Index (RRI) matrix, a reflection of its unquestionable attractiveness and limited risks relative to other markets. The US has ranked first consistently over the past three years, thanks to strong scores across the four major sub-categories. We expect this to remain the case for the foreseeable future, with no other markets expected to top the vast commercial potential of the country's pharmaceutical market, underpinned by the high per capita volume use of medicines.

The US has a RRI score of 83.9 out of 100 for Q117. This is unchanged from Q416 and Q316, and slightly higher than the 82.8 recorded in Q216. The high RRI score recorded by the US underlines the pharmaceutical market's unassailable status as the most lucrative globally. This is due to unparalleled healthcare access, considerable spending power, a high burden of disease, minimal market access barriers and intense company activity. The key risks to this positive outlook are the increasing influence of pharmacy benefit managers and greater regulation, such as the Branded Prescription Drug Fee.

Latest Updates

November 2016

US President-elect Donald Trump has said he is open to keeping key parts of President Barack Obama's healthcare bill, specifically that of the ban on insurers denying coverage for pre-existing medical conditions. He would also keep the provision that allows young adults to be covered by insurance held by their parents.

October 2016

Mylan agreed to the terms of a USD465mn settlement with the US Department of Justice and other government agencies. The settlement will resolve questions that have been raised about the classification of Mylan's EpiPen Auto-Injector and EpiPen Jr Auto-Injector (epinephrine) for purposes of the Medicaid Drug Rebate Program.

BMI Economic View

The demographic landscape in the US will support an expansionary economic growth trajectory over the medium term. More individuals will enter their prime working age (between the ages of 25 and 54), helping to counteract the opposing force of retiring 'baby boomers' (individuals born between 1946 and 1964) and pushing the labour force participation rate higher. Recovering private investment, alongside the increasing educational levels of new employees, will support an uptick in productivity growth, translating into stronger wage growth than we have seen in the past decade. We expect the US housing sector to be a major beneficiary of this trend, as rising employment and wages support residential real estate demand.

BMI Political View

The election of Donald Trump as President of the US represents a major shake-up of the established order in US politics. The Republicans last controlled both the presidency and Congress in 2006, and the nature of Trump's victory across traditionally Democratic states and against all odds (as an 80-20% underdog on the eve of the election according to betting markets) suggest that he could have significantly greater leeway in policy formation in Congress than foreseen by most. Now, the Republican Party will have its greatest degree of dominance since the 1920s, controlling the Senate, House of Representatives, a majority of state governors, and the presidency, in addition to having significant influence in the Supreme Court (with at least one and potentially more vacancies to fill in the next Congress).

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (United States 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (United States 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (United States 2012-2020)
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecasts (United States 2014-2020)
31
Industry Risk Reward Index
32
Americas Risk/Reward Index
32
United States Risk/Reward Index
39
Rewards
39
Risks
39
Regulatory Review
41
Intellectual Property Issues
56
Pricing & Reimbursement Regime
57
The November 2016 Presidential Election
59
Market Overview
61
Healthcare Sector
62
Table: Key Features Of The Affordable Care Act By Year
64
Table: Healthcare Resources (United States 2010-2015)
67
Table: Healthcare Personnel (United States 2010-2015)
67
Table: Healthcare Activity (United States 2010-2015)
68
Clinical Trials
68
Epidemiology
70
Competitive Landscape
73
Research-Based Industry
73
Table: Multinational Market Activity
73
Pharmaceutical Distribution
75
Pharmaceutical Retail Sector
75
Company Profile
76
Amgen
76
AstraZeneca
81
Eli Lilly
85
GlaxoSmithKline
89
Merck & Co
93
Pfizer
97
Demographic Forecast
101
Table: Population Headline Indicators (United States 1990-2025)
102
Table: Key Population Ratios (United States 1990-2025)
102
Table: Urban/Rural Population & Life Expectancy (United States 1990-2025)
103
Table: Population By Age Group (United States 1990-2025)
103
Table: Population By Age Group % (United States 1990-2025)
104
Glossary
106
Methodology
108
Pharmaceutical Expenditure Forecast Model
108
Healthcare Expenditure Forecast Model
108
Notes On Methodology
109
Risk/Reward Index Methodology
110
Index Overview
111
Table: Pharmaceutical Risk/Reward Index Indicators
111
Indicator Weightings
112

The United States Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United States Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the United States pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for United States, to test other views - a key input for successful budgeting and strategic business planning in the American pharmaceutical and healthcare market.
  • Target business opportunities and risks in the American pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in United States.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.